Facebook: World Allergy Organization
Twitter: World Allergy Organization
LinkedIn: World Allergy Organization
Instagram: World Allergy Organization
Back to Top

WAO Medical Book Reviews

Posted: June 21, 2016

New Drugs and Targets for Asthma and COPD
Edited by Trevor T. Hansel and Peter J. Barnes
ISBN: 978-3-8055-9566-7
eISBN: 978-3-8055-9567-4

$292.00 USD / €232.00 EUR / 248.00 CHF (eBook)
$292.00 USD / €232.00 EUR / 248.00 CHF (Hardcover)
Available from: Karger

Rohit Gaurav, MSc, PhD
Department of Medicine, National Jewish Health
Denver, Colorado, USA

Asthma and COPD are inflammatory lung diseases that have eluded our efforts to find a cure. The immense heterogeneity found in these diseases precludes approaching them with a single drug or therapy, and true disease-modifying therapies do not yet exist. However, with the advent of new research and technology, we have progressed towards identifying multiple therapeutic targets that have increased the longevity and quality of life in these patients. Increases in the incidence of both allergic asthma and COPD worldwide draw our attention to understanding the cause and pathophysiology of these difficult diseases more than ever.     

New Drugs and Targets for Asthma and COPD is a compilation of the available and novel therapies from global experts in research and science. Although the book does not include every potential therapy, it discusses the vast majority and expands the possibilities by bringing researchers and clinicians together to explore therapeutic options in asthma and COPD.  

With contributions from experts in their field from both academia and industry, this book may serve as a benchmark to researchers and clinicians alike for the latest available therapies and potential targets in asthma and COPD.

The Introduction of the New Drugs and Targets for Asthma and COPD includes a brief overview of the new drugs and potential targets. The subsections contain new bronchodilators, corticosteroids, mediator antagonists, IgE-directed therapies, immune and microbial therapies, cytokine-specific therapies, chemokine receptors, adhesion molecules, phosphodiesterase inhibitors, antioxidants, mucolytics, antiproteases, antifibrotics, macrolides, antivirals, statins, theophylline (as reversal of corticosteroid resistance), transcription factors, kinase inhibitors, nucleic acid therapy, retinoic acid and stem cells.

With different chapters, the book explores these different approaches in detail, addressing the molecular mechanisms that may be targeted for therapeutic interventions. The inclusion of drugs currently in clinical trials gives the reader additional insight into the strategies in development to combat these complex diseases. 

Assessment and Audience
This book is indeed a good source to get up to pace with the novel therapeutic strategies in asthma and COPD. From the structure of drugs to the mechanisms of their molecular targets, this book provides an excellent resource to clinicians, researchers, and pharmaceuticals.

Why read this book? How will it impact my practice?
This book is recommended to all clinicians and researchers connected with asthma and COPD to not only review the vast therapeutic options currently available but also to recognize the potential of novel therapeutic targets by understanding these diseases more thoroughly.